Fusion Antibodies PLC Ordinary Shares FAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FAB is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- GBX 3.75
- Day Range
- GBX 3.50–3.70
- 52-Week Range
- GBX 3.02–50.00
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 333.69 Mil
- Volume/Avg
- 167,778 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.88
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 46
- Website
- https://www.fusionantibodies.com
Valuation
|
Metric
|
FAB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.55 |
Price/Sales | 0.88 |
Price/Cash Flow | — |
Price/Earnings
FAB
Financial Strength
|
Metric
|
FAB
|
|---|---|
Quick Ratio | 2.32 |
Current Ratio | 3.26 |
Interest Coverage | — |
Quick Ratio
FAB
Profitability
|
Metric
|
FAB
|
|---|---|
Return on Assets (Normalized) | −103.41% |
Return on Equity (Normalized) | −162.72% |
Return on Invested Capital (Normalized) | −149.71% |
Return on Assets
FAB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cdgyynpfz | Qlzp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bgqxmtp | Qjqqb | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kdyfmsr | Qxbbyx | $97.8 Bil | |
MRNA
| Moderna Inc | Hdybsnzh | Xdvcn | $38.8 Bil | |
ARGX
| argenx SE ADR | Xmqkdsymj | Bntgf | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Lrfnncbv | Ppg | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jnyppvdcc | Mcfgsjq | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nfrwctfk | Gbcsbp | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Prgyzwlnmd | Kzxwj | $12.5 Bil | |
INCY
| Incyte Corp | Zgkzhfj | Fpzhznb | $11.5 Bil |